右心室衰竭的分子代谢与影像学进展:AHA科学声明
该科学声明总结肺动脉高压中右心室功能障碍的机制与临床意义,强调慢性压力负荷导致适应不良重构及右室-肺动脉解耦联,是晚期肺动脉高压主要死因。影像与生物标志物进展有助于检测适应不良重构,sotatercept等治疗可能降低肺血管阻力并支持右室恢复。
要点
- 右室功能障碍是肺动脉高压结局的关键预测因素,右室-肺动脉解耦联提示适应不良。
- 适应不良重构以右室扩张、纤维化、僵硬及与肺动脉解耦联为特征。
- sotatercept等治疗可能降低肺血管阻力并支持右室恢复。
核心结论
- 将右心室视为核心治疗靶点可能带来更个体化有效的干预并改善肺动脉高压及相关疾病患者结局。
研究设计与样本
- 美国心脏协会科学声明,总结肺动脉高压中右心室功能障碍的机制、临床相关性与治疗潜力。
主要发现
- 肺动脉高压进展时肺血管阻力升高使右室慢性压力负荷,初期通过肥厚性重构维持心输出量。
- 随时间推移转为适应不良重构,表现为右室扩张、纤维化、僵硬及右室-肺动脉解耦联。
- 右室-肺动脉解耦联反映右室无法在高后负荷下维持收缩力,最终导致右心衰竭。
- 右室功能障碍的认知已扩展至射血分数保留的心衰、先天性心脏病、COVID-19及左室辅助装置植入并发症。
临床怎么用
- 关注右室功能障碍作为肺动脉高压及相关疾病的关键预测指标。
- 利用影像与生物标志物创新检测适应不良性右室重构。
- 考虑sotatercept等可能降低肺血管阻力并支持右室恢复的治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Right ventricular (RV) dysfunction is a key predictor of outcomes in pulmonary hypertension (PH), substantially contributing to illness and death. As PH progresses, increased pulmonary vascular resistance places chronic pressure overload on the right ventricle. Initially, the right ventricle adapts through hypertrophic remodeling, thickening the heart wall to maintain cardiac output. Over time, this adaptive phase shifts to maladaptive remodeling, marked by RV dilation, fibrosis, stiffness, and decoupling from the pulmonary artery, known as RV-pulmonary arterial uncoupling. This uncoupling reflects the inability of the right ventricle to sustain contractility against elevated afterload, ultimately leading to right heart failure, the primary cause of death in late-stage PH. Awareness of RV dysfunction has grown, extending beyond PH and pulmonary arterial hypertension to systemic conditions, such as heart failure with preserved ejection fraction, congenital heart disease, COVID-19, and complications of left ventricular assist device implantation. Research is increasingly focused on understanding the molecular and hemodynamic drivers of RV failure, including inflammation and altered cellular signaling. Innovations in imaging and biomarker discovery are improving the detection of maladaptive RV remodeling. Promising treatments, such as the activin signaling inhibitor sotatercept, may reduce pulmonary vascular resistance and support RV recovery. Further work is needed to enhance RV function and prevent failure. This review summarizes current knowledge on RV dysfunction in PH, emphasizing its mechanisms, clinical relevance, and therapeutic potential. Recognizing the right ventricle as a central therapeutic target may lead to more personalized, effective interventions and improved patient outcomes in PH and related conditions.
引用
- Pullamsetti SS, Vanderpool RR, de Man F, et al. Advanced Molecular, Metabolic, and Imaging Approaches to Characterizing Right Ventricular Failure: A Scientific Statement From the American Heart Association. Circulation. 2026. PMID: 41924886. doi:10.1161/CIR.0000000000001422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。